gonorrhea
DESCRIPTION
Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention. Gonorrhea. Gonorrhea—Rates, United States, 1941–2009. Rate (per 100,000 population). 500. 400. 300. 200. 100. 0. 1941. 1946. 1951. 1956. 1961. 1966. 1971. 1976. 1981. 1986. 1991. 1996. 2001. 2006. - PowerPoint PPT PresentationTRANSCRIPT
GONORRHEA
Sexually Transmitted Disease Surveillance 2009Division of STD Prevention
Gonorrhea—Rates, United States, 1941–2009
Rate (per 100,000 population)
200620011996199119861981197619711966196119561951194619410
100
200
300
400
500
Year
Gonorrhea—Rates by Sex, United States, 1990–2009
200820062004200220001998199619941990
TotalWomenMen
Rate (per 100,000 population)
0
100
200
300
400
1992
Year
Gonorrhea—Rates by Region, United States, 2000–2009
2009200820072006200520042003200220012000
SouthNortheastMidwestWest
Rate (per 100,000 population)
0
50
100
150
200
250
300
Year
Gonorrhea—Rates by State, United States and Outlying Areas, 2009
NOTE: The total rate of gonorrhea for the United States and outlying areas (Guam, Puerto Rico, and Virgin Islands) was 97.8 per 100,000 population.
34.9
29.4
63.2
66.4
8.3
144.3
Puerto Rico5.8
Guam33.5
23.5 10.9
87.2
81.4
185.7
120.4
7.2
12.5
54.5
13.942.8
77.2
44.1
92.4
246.4160.8
141.3
113.9
150.4
100.3
139.2
147.0
107.2
127.5
109.8
128.3
204.0
156.2
154.7
89.626.257.2
50.0
55.2
89.4
<19.0 (n = 8)
Rate per 100,000population
19.1–100.0 (n = 24)
>100.0 (n = 22)
49.0
VirginIslands104.7
VT
NH
MA
RI
CT
NJ
DE
MD
DC
8.0
8.6
30.4
30.6
73.1
54.8
111.2
113.5
432.7
Gonorrhea—Rates by County, United States, 2009
<19.0 (n = 1,405)
Rate per 100,000population
19.1–100.0 (n = 1,129)
>100.0 (n = 607)
Gonorrhea—Rates by Age and Sex, United States, 2009
750 600 450 300 150 0 0 150 300 450 600 750
10–14
15–19
20–24
25–29
30–34
35–39
40–44
45–54
55–64
65+
Total
5.0
250.0
407.5
238.9
145.0
85.6
60.8
33.6
92.2
2.7
11.4
25.3
568.8
555.3
229.4
106.2
47.6
22.9
8.7
105.7
0.5
2.1
Men WomenRate (per 100,000 population)
Age
Gonorrhea—Rates by Age Among Women Aged 15–44 Years, United States, 2000–2009
Rate (per 100,000 population)
Year
0
200
400
600
800
1,000
2009200820072006200520042003200220012000
35–3940–44
30–34
25–2920–2415–19
Age Group
Gonorrhea—Rates by Age Among Men Aged 15–44 Years, United States, 2000–2009
0
150
300
450
600
750
2009200820072006200520042003200220012000
Rate (per 100,000 population)
Year
35–3940–44
30–34
25–2920–2415–19
Age Group
Gonorrhea—Rates by Race/Ethnicity, United States,
2000–2009
0
100
200
300
400
500
600
700
800
2009200820072006200520042003200220012000
WhitesHispanicsBlacksAsians/Pacific IslandersAmerican Indians/Alaska Natives
Rate (per 100,000 population)
Year
Gonorrhea—Cases by Reporting Source and Sex, United States,
2000–2009
* STD = sexually transmitted disease.
0
40
80
120
160
200
2009200820072006200520042003200220012000
STD Clinic, WomenSTD Clinic, MenNon-STD Clinic, WomenNon-STD* Clinic, Men
Cases (in thousands)
Year
Gonorrhea—Percentage of Reported Cases by Sex and Selected Reporting Sources,
United States, 2009
* HMO = health maintenance organization; STD = sexually transmitted disease; HD = health department.NOTE: These categories represent 71.9% of cases with known reporting source. Of all cases, 10.3% had a missing or unknown reporting source.
Percentage
Men Women0
5
10
15
20
25
30
35STD* Clinic
Private Physician/HMO*
Other HD* Clinic
Family Planning Clinic
Emergency Room
Gonorrhea—Positivity Among Women Aged 15–24 Years Tested in Family Planning Clinics, by State, Infertility Prevention Project, United States and
Outlying Areas, 2009
* States/areas not meeting minimum inclusion criteria.NOTE: Includes states and outlying areas that reported positivity data on at least 500 women aged 15–24 years who were screened during 2009.
1.0
3.4
1.1
0.2
Puerto Rico0.1
VirginIslands
2.0
0.0
0.5
0.8
2.0
2.0
0.1
0.3
1.6
0.2
0.8
0.40.3
0.3
0.12.7
2.41.8
2.0
1.2
1.2
1.0
1.8
1.4
1.1
0.6
1.0
0.8
2.1
1.9
1.4
0.50.20.4
0.4
0.5
1.0
* (n = 4)
Positivity (%)
<1.0 (n = 24)
1.0–1.9 (n = 16)>2.0 (n = 9)0.5
VT
NH
MA
RI
CT
NJ
DE
MD
DC
0.2
0.3
0.6
1.2
1.3
2.5
Gonococcal Isolate Surveillance Project (GISP)—Location of Participating Sentinel Sites and Regional Laboratories, United States, 2009
Birmingham
Phoenix Los Angeles
Orange Co. San
Diego
San Francisco
Denver
Miami
Atlanta
Honolulu
Tripler AMC
Chicago
New Orleans
Baltimore
Detroit
Minneapolis
Kansas City Las
Vegas
Albuquerque
New York City
Greensboro
Cincinnati
Cleveland
Oklahoma City
Portland
Philadelphia
Dallas
Richmond
Seattle
Sentinel Sites
Sites and Regional Labs
Gonococcal Isolate Surveillance Project (GISP)—Distribution of Minimum Inhibitory
Concentrations (MICs) to Ceftriaxone Among GISP Isolates, 2005–2009
0
20
40
60
80
100
0.250.1250.060.030.015<0.008
2006
2005
Percentage
2007
2009
2008
MICs (µg/ml)
Gonococcal Isolate Surveillance Project (GISP)—Distribution of Minimum Inhibitory
Concentrations (MICs) to Cefixime Among GISP Isolates, 2005–2006 and 2009
NOTE: Isolates were not tested for cefixime susceptibility in 2007 and 2008.
0
20
40
60
80
100
0.50.250.1250.060.03<0.015
Percentage
MICs (µg/ml)
2006
2005
2009
Gonococcal Isolate Surveillance Project (GISP)—Distribution of Minimum Inhibitory
Concentrations (MICs) to Azithromycin Among GISP Isolates, 2005–2009
0
10
20
30
40
1684210.50.250.1250.06<0.03
2006
2005
Percentage
2007
2009
2008
MICs (µg/ml)
Gonococcal Isolate Surveillance Project (GISP)—Percentage of Neisseria gonorrhoeae Isolates with Resistance or Intermediate Resistance to
Ciprofloxacin, 1990–2009
NOTE: Resistant isolates have ciprofloxacin minimum inhibitory concentrations (MICs) >1 µg/ml. Isolates with intermediate resistance have ciprofloxacin MICs of 0.125–0.5 µg/ml. Susceptibility to ciprofloxacin was first measured in GISP in 1990.
0
5
10
15
20
20092008200720062005200420032002200120001999199819971996199519941993199219911990
Intermediate Resistance
Resistance
Percentage
Year
Gonococcal Isolate Surveillance Project (GISP)—Penicillin, Tetracycline, and
Ciprofloxacin Resistance Among GISP Isolates, 2009
NOTE: PenR = penicillinase producing Neisseria gonorrhoeae and chromosomally mediated penicillin-resistant N. gonorrhoeae; TetR = chromosomally and plasmid mediated tetracycline-resistant N. gonorrhoeae; and QRNG = quinolone-resistant N. gonorrhoeae.
PenR/QRNG
PenR
TetR/QRNG
PenR/TetR
QRNG
PenR/TetR/QRNG
TetR
Susceptible
76.5%
1.1%0.9%2.2%
2.1%
7.9%
5.5%
3.8%
Gonococcal Isolate Surveillance Project (GISP)—Drugs Used to Treat Gonorrhea Among GISP
Participants, 1988–2009
NOTE: For 2009, “Other” includes no therapy (1.5%), azithromycin 2 g (1.7%), and other less frequently used drugs.
0
20
40
60
80
100
1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008
Ceftriaxone 125 mgSpectinomycin
Ceftriaxone 250 mgCefixime
Penicillins
Ciprofloxacin
Tetracyclines
Ofloxacin
Other
Percentage
Year
Other Cephalosporins
For more information please contact Centers for Disease Control and Prevention1600 Clifton Road NE, Atlanta, GA 30333Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348E-mail: [email protected] Web: www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention
Division of STD Prevention